Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Pelthos Therapeutics (PTHS), Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Fri Mar 20, 2:14PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pelthos Therapeutics (PTHS) and Sarepta Therapeutics (SRPT) with bullish sentiments.

Claim 70% Off TipRanks Premium

Pelthos Therapeutics (PTHS)

Alliance Global Partners analyst James Molloy reiterated a Buy rating on Pelthos Therapeutics today and set a price target of $75.00. The company’s shares closed last Thursday at $22.25.

According to TipRanks.com, Molloy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.8% and a 19.2% success rate. Molloy covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Intensity Therapeutics, Inc., and Barinthus Biotherapeutics. ;'>

Currently, the analyst consensus on Pelthos Therapeutics is a Strong Buy with an average price target of $58.00, which is a 132.5% upside from current levels. In a report issued on March 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.

See today’s best-performing stocks on TipRanks >>

Sarepta Therapeutics (SRPT)

In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Sarepta Therapeutics, with a price target of $31.00. The company’s shares closed last Thursday at $16.62.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -0.6% and a 36.0% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Cartesian Therapeutics, and ACADIA Pharmaceuticals. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $21.28 average price target, which is a 25.6% upside from current levels. In a report issued on March 17, Oppenheimer also maintained a Buy rating on the stock with a $37.00 price target.

Read More on PTHS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).